Plain-language summary

This trial is evaluating Autologous Hematopoietic Stem Cell Transplantation and Allogenic stem cell transplant (ASCT) as a treatment for people newly diagnosed with T-cell lymphoma. The study measures how well this treatment works and monitors for side effects. This trial does not currently list US sites.

Who can join (key eligibility)

• Age 18 Years to 70 Years years
• Newly diagnosed, not yet treated
• Must be well enough for treatment (adequate performance status)

Final eligibility is determined by the trial team. This list is a starting point only.

What's being tested

Autologous Hematopoietic Stem Cell Transplantation (PROCEDURE): Auto-HSCT involves the infusion of the patient's own previously collected stem cells. | Allogenic stem cell transplant (ASCT) (PROCEDURE): ASCT involves the infusion of stem cells collected from a donor (genetically similar, but not identical).

Drugs / treatments

Autologous Hematopoietic Stem Cell Transplantation, Allogenic stem cell transplant (ASCT)

Treatment length

Ask the trial team for details

Visit frequency

Ask the trial team for details